Diametrics Medical, Inc. /Intermittent Testing Business/

MISSION, Kan., Dec. 5, 2022 /PRNewswire/ -- (Family Features) For many people who wish to work toward a healthier weight, one of the greatest obstacles is figuring out where to begin. These tips from SlimFast consultant and registered dietitian Maryann Walsh show it doesn't take a drastic lifestyle overhaul to make an impact. Continue Reading Photo courtesy of SlimFast Eat Mindfully Many people who struggle with their weight benefit from being more conscious about what they're eating and why. For example, consider your eating habits, such as eating even when you're not hungry whether that's because it's mealtime and you think you should eat, you're satisfying a craving or using a tasty snack to cope with stress. Recognizing why you're eating is an important step toward correcting destructive eating patterns, but so is paying attention to the other details of the eating experience, including what you eat and how it makes you feel. Ultimately, this may allow you to choose healthier foods that nourish your body for the long-term, rather than the brief satisfaction that comes with less nutritious choices. Consider Intermittent Fasting One weight-loss method many people find success using is intermittent fasting, which involves abstaining from all food and beverages for a specified time period each day or week. While going too long without food can sometimes lead to excess hunger then overeating later, in shorter, controlled fasting timeframes one can often more easily achieve a caloric deficit, which is required for weight loss. Prepare for your fasting phase by choosing foods that support satiety. Options like SlimFast's Intermittent Fasting line of meal bars and protein shakes can help avoid a sense of deprivation with tasty flavors like the Vanilla Cupcake Snack Shake Mix and Vanilla Almond Crunch Complete Meal Bar. The shake mixes deliver 15 grams of slow-digesting protein, compared to whey protein, to help curb hunger, along with more than 20 vitamins and minerals. The meal bars clock in with 15 grams of protein and 10 grams of fiber. Manage Stress When you're stressed, your body produces cortisol, which also raises insulin and can drive hunger and trigger cravings for comfort foods. In fact, that's the very reason people tend to overeat when they're under pressure. Light exercise and meditative practices can help you manage your mental strain. You might also consider talk therapy with a friend or professional or spend time unwinding with a book or music. Get Proper Sleep Poor sleep habits affect your weight in numerous ways. One is that when you're feeling tired, your hunger and satiety hormones, ghrelin and leptin, can be affected, leading to an increase in caloric intake and subsequent weight gain. Additionally, when you're tired, you're more likely to take shortcuts like skipping workouts or opting for unhealthy convenience foods. All are reasons to make better rest a bigger priority. Track Eating and Exercise When you're not paying attention to what you eat and how you move, you may not even realize how your habits are affecting your health. Logging what you eat, especially if you use a tool like an app that helps you see the nutrition breakdown, may give you a clearer idea of the quality and quantity of your intake. Similarly, when you're specifically writing down the time you're committing to physical activity, you'll find it easier to identify patterns and pinpoint where you can make adjustments to increase your exercise. Visit SlimFast.com to find more resources on weight management and intermittent fasting. 3 Tips for Intermittent Fasting If you're new to the idea of intermittent fasting, these tips can help you find greater success so you can see results. Pace yourself. Make a gradual transition so your body gets used to going without food for shorter periods of time before you work up to extended fasting periods. Stay hydrated. Avoid confusing thirst for hunger by upping your fluid intake. Staying hydrated and energized while you fast helps keep fatigue and brain fog at bay. Options like fruit-flavored SlimFast Intermittent Fasting Energizing Hydration Supplement Drink Mix won't break your fast and can help you add variety as a flavorful alternative to water. They can provide the energy and focus you need between meals and are perfect for those who feel groggy or run-down while fasting. Set goals. Know what you want to achieve and why, so your "why" can keep motivating you to follow your intermittent fasting plan even when you're tempted to quit. Photo courtesy of Getty Images (woman and man exercising) Michael French [email protected] 1-888-824-3337 editors.familyfeatures.com About Family Features Editorial Syndicate A leading source for high-quality food, lifestyle and home and garden content, Family Features provides readers with topically and seasonally relevant tips, takeaways, information, recipes, videos, infographics and more. Find additional articles and information at Culinary.net and eLivingToday.com. SOURCE Family Features Editorial Syndicate

Honoring the brand's 80s roots, SlimFast and the go-to fitness guru host a throwback-inspired workout class where fans can travel through the decades – starting with the 80s to present day. DOWNERS GROVE, Ill., Nov. 10, 2022 /PRNewswire/ -- For 40 years SlimFast, a leading global weight management brand part of Glanbia Performance Nutrition, has helped millions of Americans manage their weight. Throughout the years, SlimFast has remained an industry leader – beginning with its popular shake mixes in the 80s, to evolving its line to include High Protein, Keto products and most recently, Intermittent Fasting, to meet today's lifestyles and preferences. Continue Reading SlimFast Elevates Brand Refresh with New Campaign Partnering with 80s Fitness Icon Denise Austin Tweet this Partnering with 80s Fitness Icon Denise Austin, SlimFast hosts a throwback-inspired workout class where fans can travel through the decades – starting with the 80s to present day. Join in on Friday, November 11 at 9:30 am CST on Denise Austin’s YouTube channel for a fun workout. The recent brand refresh includes new packaging and messaging. The latest addition to the SlimFast line includes Intermittent Fasting with protein shake mixes, hydrating electrolyte drink mixes and complete meal bars – each product can support specific phases, whether it’s to help curb hunger, provide nutrients or to provide energy and flavor to the fasting cycle. Denise Austin leads her daughter Katie Austin and friends in the SlimFast loves the 80s Throwback Fitness Class while taking a hydration break with Intermittent Fasting Energizing Hydration Drink Mix in Fruit Punch and Berry Lemonade. "As consumers desire more flexibility and empowerment while achieving their weight management goals, SlimFast has launched its "Deliciously Doable" platform with customizable products and resources to meet consumers where they are on their weight management journey," said Sarah Lombard, senior brand director at SlimFast. "To honor our past and educate consumers on the SlimFast of 'today' we've partnered with fitness icon Denise Austin and her daughter to showcase simple solutions as a part of the brand's Deliciously Doable approach." To celebrate the SlimFast of today and pay homage to the brand's 1980s origins, 80s fitness icon Denise Austin is joined by her favorite guest – her daughter and fitness personality, Katie Austin, and her friends – to release the SlimFast loves the 80s Throwback Fitness Class this November. The class will incorporate then-and-now workout moves, along with fashion and pop-culture surprises as fans move through the decades with SlimFast. Additionally, throughout the class, the mother-daughter duo will demonstrate how SlimFast's Deliciously Doable approach is real simple, real tasty - all while offering real results.1 Leading up to the class, SlimFast will share Denise Austin's tips and tricks, behind-the-scenes footage, and SlimFast product picks on Instagram at @SlimFast. To join in on the fun and participate in the conversation with @SlimFast and @DeniseAustin fans can follow #SlimFastToday. In true #FlashBackFriday form, the SlimFast loves the 80s Throwback Fitness Class will take place on November 11 at 9:30 am CST on Denise Austin's YouTube Channel. Fans can be one of the first to take the on-demand, virtual workout class shared first on Instagram @SlimFast, or participate in the fun on YouTube. "For 40 years, I've focused on providing attainable solutions for women to reach their goals," said Denise Austin. "I am proud to partner with SlimFast – a leader in the industry for more than 40 years and a brand committed to inspiring confidence while offering support that's 'real simple' and fits into real life, whatever that looks like." This activation is a continuation of the "Same Difference" 360-ad campaign SlimFast released in September that incorporates a bit of humor, a nostalgic look at the brand's classic 80s past and how it has evolved into the brand it is today. The ad rolled out on television nationwide and across digital and social platforms. The brand refresh also includes new packaging and messaging. For more information on the SlimFast brand, products store locations, please visit slimfast.com. About SlimFast® Part of Glanbia Performance Nutrition, SlimFast was founded to help people achieve their weight loss goals safely, reliably and with ease. Since 1977, the SlimFast plan has helped millions of people around the world lose and manage their weight. The creator of the meal-replacement shake category, SlimFast now features a full assortment of delicious ready-to-drink and shake mixes, snacks and meal replacement bars. SlimFast products can be found in specialty and mass retail stores nationwide and most online retailers. For more information, visit slimfast.com or manage your weight your way through the SlimFast Together App, available on Apple and Google Play. Follow the brand on Facebook, Instagram, Twitter and Pinterest. About Glanbia Performance Nutrition Glanbia Performance Nutrition (GPN) is a wholly owned subsidiary of Glanbia (ISE/LSE: GLAPF), a global nutrition company. GPN's mission is to inspire people everywhere to achieve their performance and healthy lifestyle goals through their leading health and wellness brands, which include Optimum Nutrition®, SlimFast®, think!®, Isopure®, Amazing Grass® and BSN®, among others. Global revenues for GPN in 2021 were approximately $1.4 billion. Visit glanbiaperformancenutrition.com or glanbia.com to learn more. Follow us on Instagram, Twitter and LinkedIn. 1Real results may vary based on the use of the SlimFast Plan. See SlimFast.com for details. SOURCE Glanbia Performance Nutrition (NA), Inc.

July 18, 2022 12:00 UTC SAN DIEGO & TOKYO--(BUSINESS WIRE)-- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced publication of data from the Phase 1b clinical study of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor, in patients with relapsed or refractory (R/R) B-cell malignancy in The Lancet Oncology. The published data demonstrate that an intermittent dosing regimen of zandelisib resulted in lower cumulative risk of Grade 3 or worse adverse events of special interest compared to a continuous daily dosing regimen without loss of efficacy. The publication, entitled "Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial," is available on the journal website. “The results observed in our Phase 1b study reinforce the potential of zandelisib, an investigational clinical candidate, to provide a well-tolerated clinical pro as a single-agent or in combination with other therapies without a loss of efficacy via a unique intermittent schedule compared to continuous daily dosing,” said Richard Ghalie, M.D., chief medical officer of MEI Pharma. “We remain encouraged by zandelisib’s potential as we continue its development using the intermittent schedule as an oral, chemotherapy-free, time-limited, therapeutic option to meet the needs of patients.” “Based on the results of the Phase 1b study, zandelisib could establish a potential alternative to chemotherapy with a unique dosing schedule for this class, both as a single agent and in combination with other drugs,” said Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of R&D Division of Kyowa Kirin. “We will continue to work with MEI to develop new treatment options for patients with B-cell malignancies.” The Phase 1b study (NCT02914938) is an open-label, dose escalation and expansion study evaluating zandelisib in patients with B-cell malignancies. The manuscript reported on a total of 97 patients, including 31 patients in the dose escalation stage that established 60 mg once daily as the recommended Phase 2 dose. The study evaluated zandelisib in 56 patients as a monotherapy and 41 patients in combination with rituximab. Zandelisib was administered either on a continuous schedule of 60 mg once daily (n=38) or an intermittent dosing schedule of 60 mg once daily for the initial two 28-day cycles followed by the intermittent dosing (ID) schedule of 60 mg once daily on days 1-7 in cycles ≥3 (n=59). In the initial monotherapy dose-finding part of the study, no dose-limiting toxicities were observed across the evaluated doses of 60 mg, 120 mg and 180 mg given daily continuously, and anti-tumor activity was similar across doses. With a median duration of treatment of 10.4 months and 15.2 months, in the continuous and intermittent dosing group respectively, Grade 3 or worse adverse events of special interest occurred less frequently in the intermittent dosing group than in the continuous dosing group. For example, Grade 3 diarrhea or colitis in 8% vs 24%, and Grade 3 lung infection or pneumonia in 2% vs 16%, of patients in the intermittent dosing group vs the continuous dosing group, respectively. Grade 3 or worse AST or ALT elevation (5%) and rash (5%) were uncommon with each dosing schedules. There was a continued increased risk of Grade 3 diarrhea or colitis in the continuous dosing group, compared with a decreased risk over time in the intermittent dosing group after switching to the intermittent dosing. At a median follow-up of 24.9 months in the continuous dosing group and 15.7 months (95% CI 6·5-33·9) in the intermittent dosing group the cumulative incidence of Grade 3 or worse adverse events of special interest was 45% in the continuous dosing group and 20% in the intermittent dosing group. Intermittent dosing showed comparable efficacy to continuous dosing. Patients with indolent B-cell malignancies (follicular lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, and marginal zone lymphoma) demonstrated an objective overall response rate of 87%. The published Phase 1b safety and efficacy results for zandelisib 60 mg once daily on an intermittent dosing schedule warranted initiating the ongoing global Phase 2 TIDAL and Phase 3 COASTAL studies evaluating zandelisib alone or in combination with rituximab, respectively. About Zandelisib Zandelisib, a selective PI3Kδ inhibitor, is an investigational cancer treatment being developed as an oral, once-daily, potential therapeutic option for patients with B-cell malignancies. Clinical trials are investigating the efficacy and safety of zandelisib as a single agent and in combination with other modalities while administered on an Intermittent Dosing Regimen (ID) and in a time-limited manner when dosed in combination. The ID leverages molecular and biologic properties specific to zandelisib. Ongoing zandelisib studies include the cohort in TIDAL evaluating patients with r/r marginal zone lymphoma (MZL) and continuing evaluation of the cohort of patients in the study with r/r FL. Also ongoing is the Phase 3 COASTAL study (NCT04745832), comparing zandelisib plus rituximab to standard of care chemotherapy plus rituximab in patients with r/r FL or MZL who received more than one prior line of therapy, which must have included an anti-CD20 antibody in combination with chemotherapy or lenalidomide. COASTAL, which is also evaluating time-limited intermittent administration of zandelisib, is intended to support marketing applications in the U.S. and globally. Other ongoing studies include a Phase 2 pivotal study in Japan (NCT04533581) in patients with indolent B-cell non-Hodgkin's lymphoma (iB-NHL) without small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), and Waldenström's macroglobulinemia (WM) conducted by Kyowa Kirin. In March 2020, the FDA granted zandelisib Fast Track designation for the treatment of adult patients with r/r follicular lymphoma who have received at least two prior systemic therapies. In November 2021, the FDA granted zandelisib Orphan Drug designation for the treatment of patients with follicular lymphoma. In April 2020, MEI and Kyowa Kirin entered a global license, development, and commercialization agreement to further develop and commercialize zandelisib. MEI and Kyowa Kirin will co-develop and co-promote zandelisib in the U.S., with MEI booking all revenue from the U.S. sales. Kyowa Kirin has exclusive commercialization rights outside of the U.S. About MEI Pharma MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently in ongoing clinical trials which may support marketing approvals with the U.S. Food and Drug Administration and other regulatory authorities globally. Each of MEI Pharma's pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options. For more information, please visit . Follow us on Twitter @MEI_Pharma and on LinkedIn. About Kyowa Kirin Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based global specialty pharmaceutical company with a heritage of more than 70 years, the company applies cutting-edge science, including expertise in antibody research and engineering, to address the needs of patients across multiple therapeutic areas such as nephrology, oncology, immunology/allergy and neurology. Across its four regions – Japan, Asia Pacific, North America and EMEA/International – Kyowa Kirin focuses on its purpose, to make people smile, and is united by its shared values of commitment to life, teamwork, innovation and integrity. Learn more about the Company at . Forward-Looking Statements Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the results of our clinical trials of zandelisib, the anticipated timing of our submission of an FDA marketing application for zandelisib, the anticipated timing of the disclosure of the final study data for our Phase 2 TIDAL trial, the timing and success of enrollment for our Phase 3 COASTAL trial, our projected financial position and our expected cash runway, the overall advancement of our product candidates in clinical trials and our plans to continue development of our product candidates. We may in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; the availability or appropriateness of utilizing the FDA’s accelerated approval pathway for our product candidates; final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; costs and delays in the development and/ or FDA approval of our product candidates, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; the risk that our clinical trials are discontinued or delayed for any reason, including for safety, tolerability, enrollment, manufacturing or economic reasons; the impact of the COVID-19 pandemic on our industry and individual companies, including on our counterparties, the supply chain, the execution of our clinical development programs, our access to financing and the allocation of government resources; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.